{"organizations": [], "uuid": "d639b158de9433e2303d172943a48c1c10ca6410", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180223.html", "section_title": "Archive News &amp; Video for Friday, 23 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-episurf-medical-presents-strategy/brief-episurf-medical-presents-strategy-update-idUSASM000JNN", "country": "US", "domain_rank": 408, "title": "BRIEF-Episurf Medical Presents Strategy Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.071, "site_type": "news", "published": "2018-02-23T15:54:00.000+02:00", "replies_count": 0, "uuid": "d639b158de9433e2303d172943a48c1c10ca6410"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-episurf-medical-presents-strategy/brief-episurf-medical-presents-strategy-update-idUSASM000JNN", "ord_in_thread": 0, "title": "BRIEF-Episurf Medical Presents Strategy Update", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "asia", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fina", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - EPISURF MEDICAL AB:\n* EPISURF MEDICAL PRESENTS STRATEGY UPDATE, NEW EXTERNAL FINANCING AND LONG-TERM OPERATING TARGETS\n* ‍IS CLOSE TO LAUNCHING AN IMPORTANT AND COMPREHENSIVE CLINICAL MULTICENTER STUDY IN US AND EUROPE​\n* ‍HAS ENTERED INTO EARLY COLLABORATIVE DISCUSSIONS REGARDING US MARKET.​\n* ‍LONG-TERM PROFITABILITY GOAL: EPISURF MEDICAL TARGETS A LONG-TERM OPERATING MARGIN OF 40%​\n* HAS TAKEN DECISION TO PURSUE A CLINICAL STUDY AIMED AT GAINING FDA-APPROVAL FOR EPISEALER KNEE TECHNOLOGY​\n* ‍WILL ESTABLISH ITS PATIENT-SPECIFIC TECHNOLOGY IN TREATMENT ALGORITHM FOR FOCAL CARTILAGE AND BONE LESIONS​\n* ‍ESTIMATES ADDRESSABLE MARKET FOR EPISEALER KNEE IMPLANTS IN EUROPE, ASIA AND US AMOUNTS TO 150,000 PATIENTS ANNUALLY​\n* ‍SIGNED AN AGREEMENT RELATING TO A FINANCING OF UP TO SEK 70 MILLION​\n* ‍IS CONSIDERING ADDITIONAL EUROPEAN MARKETS​ * ‍ENGAGED IN DISTRIBUTOR DISCUSSIONS IN A NUMBER OF MIDDLE EASTERN MARKETS.​\n* ‍IS IN EARLY DISTRIBUTOR DISCUSSIONS FOR A NUMBER OF ASIAN MARKETS​\n* ‍AIMS AT STARTING CLINICAL STUDY FOR PURPOSE OF RECEIVING FDA APPROVAL FOR MARKETING OF EPISEALER TECHNOLOGY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-23T15:54:00.000+02:00", "crawled": "2018-02-24T13:29:48.063+02:00", "highlightTitle": ""}